ABSTRACT
Background and Purpose: Cytokines are among the many immune system factors involved in diabetes pathogenesis. The level of cytokines expression such as IFN- delta is varying in individuals and societies. Due to the fact that diabetes nephropathies are known as inflammatory disorders and the role of cytokines especially IFN- delta in the establishment of inflammations is well understood, the present study was aimed to examine serum level of IFN-delta in type 2 diabetes patients with nephropathy complications
Material and methods: In this cross sectional descriptive study, serum samples were obtained from 100 type 2 diabetes patients with nephropathy and 100 healthy controls for the analysis of IFN- delta serum level [eBiosense, ESP]. Consent forms were also filled out by patients and healthy controls according to the rules and regulations of Zahedan Islamic Azad University Ethical Committee. The obtained data and questionnaires were analyzed in SPSS using ANOVA; p<0.05 was considered as significant
Results: The mean serum level of IFN- delta was 16.09 +/- 7.74 pg/ml and 4.03 +/- 2.00 pg/ml in nephropathic patients and healthy controls, respectively. Statistical analysis of the data showed that the difference in the IFN- delta level was not significant in nephropathic patients and controls
Conclusion: Based on the non-significant differences between the two groups, it seems that there is no association between the level of serum IFN- delta and nephropathy in type 2 diabetics
ABSTRACT
Background: although type-2 mellitus diabetes is the most common type of diabetes, it's main cause yet to be identified. Chemokines and their receptors are probable effective systems on diabetes. CCR5 is a chemokine receptor playing an important role in immune responses. Studies showed that the known delta32 mutation in CCR5 gene leads to disorder in the expression and function of this receptor. Hence, this project aimed to analyze the known delta32 mutation in CCR5 chemokine receptor
Materials and methods: blood samples were collected from 200 type 2 diabetic patients and 300 healthy adult controls on EDTA pre-coated tubes. DNA was extracted using commercial kit. DNA samples were analyzed for delta32 mutation by Gap-PCR in diabetic patients in compared to controls. The demographic information was collected through questionnaire
Results: our results showed that none of the diabetic patients displayed CCR5 delta32 mutation. While 2 out of 300 healthy controls had heterozigotic form of this mutation. Statistical analysis didn't show any significant difference between the two groups
Conclusion: several different studies analyzed the relation of this mutation with different types of diseases including diabetes. All studies failed to find a relation between this mutation and type 2diabetes. Since these studies were performed in different geographical points and races, we studied this mutation in Rafsanjani's population. Based on the results of our study it could be probably concluded that this mutation does not play a key role in the establishment of type 2 diabetes